Evidence map›Paper›PMID 42243280›Full record

ArticleScientific reports2026

Understanding indeterminate HIV serology through antigen-band pattern analysis of INNO-LIA and recomLine HIV confirmatory assays.

Israa M Salameh, Shaden Abunasser, Nadin Younes, Parveen B Nizamuddin, Salma Younes, Sara Abdelmohsen, Affra Faiz Al-Farsi, Mazen N Abouassali, Manal Elshaikh, Ibrahim W Karimeh and 10 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Israa M Salameh *Biomedical Research Center, Qatar University, Doha, 2713, Qatar.
Shaden Abunasser *Biomedical Research Center, Qatar University, Doha, 2713, Qatar.
Nadin YounesBiomedical Research Center, Qatar University, Doha, 2713, Qatar.
Parveen B NizamuddinBiomedical Research Center, Qatar University, Doha, 2713, Qatar.
Salma YounesBiomedical Research Center, Qatar University, Doha, 2713, Qatar.
Sara AbdelmohsenDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, 2713, Qatar.
Affra Faiz Al-FarsiLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Mazen N AbouassaliLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Manal ElshaikhLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Ibrahim W KarimehLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Mohammed A IbrahimLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Mutaz M AliLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Samar A MohamedLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Ibrahim Al ShaarLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Christian MeyerMIKROGEN GmbH, Anna-Sigmund-Str. 10, 82061, Neuried, DE, Germany.
Hadi M YassineBiomedical Research Center, Qatar University, Doha, 2713, Qatar.
Laith J Abu-RaddadInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, 24144, Qatar.
Houssein AyoubMathematics Program, Department of Mathematics and Statistics, College of Arts and Sciences, Qatar University, Doha, 2713, Qatar.
Gheyath K NasrallahBiomedical Research Center, Qatar University, Doha, 2713, Qatar. gheyath.nasrallah@qu.edu.qa.
Ahmed IsmailLaboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar. aismail@MOPH.GOV.QA.

Funding

Qatar National Research Fund GSRA8-L-1-0501-21022Qatar National Research Fund NPRP13S-0128-200185Qatar Research, Development and Innovation Council ARG01-0524-230321Qatar University QUCG-CAS-23/24-114
6 · The paper itself

Abstract

Indeterminate Human Immunodeficiency Virus (HIV) serological results remain a major challenge in confirmatory diagnosis, delaying reporting and clinical decision-making. The INNO-LIA HIV I/II Score assay, a widely used confirmatory line immunoassay, frequently produces indeterminate profiles that complicate interpretation. This study evaluated the Mikrogen recomLine HIV-1/2 IgG assay against INNO-LIA, incorporating HIV-1 RNA PCR as an adjudicative reference within the Architect-reactive samples, with emphasis on antigen-band patterns underlying indeterminate results. A total of 180 archived serum samples previously tested by the Architect HIV Ag/Ab Combo and INNO-LIA were retested using recomLine; 80 Architect-reactive samples underwent HIV-1 RNA PCR testing. When only definitive results were considered, recomLine demonstrated complete agreement with INNO-LIA. When indeterminate results were included as non-concordant, specificity was 98.3% (114/116). INNO-LIA produced more indeterminate results than recomLine (13.3% vs. 2.8%), mainly due to isolated gp41 reactivity. RecomLine reclassified 85% of INNO-LIA indeterminate samples, all of tested PCR-negative. These findings provide insights into mechanisms underlying indeterminate HIV serology, suggesting that incomplete or isolated antigenic responses, particularly gp41, are major contributors. No HIV-2 monoinfection or HIV-1/2 dual infections were identified. Overall, recomLine reduced indeterminate outcomes while maintaining high diagnostic accuracy, supporting its role as a confirmatory assay.

Indexed as

AIDS SerodiagnosisHIV-1HIV-2HIV AntibodiesHIV AntigensHIV InfectionsHumansImmunoassayImmunoglobulin GRNA, ViralSensitivity and SpecificitySerologic TestsHIV AntibodiesHIV AntigensImmunoglobulin GRNA, ViralAntigenic analysisHIVIndeterminate resultsMikrogen recomLine HIV1/2

Identifiers

PMID42243280
PMCPMC13478285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.